A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)

Researchers are looking for new ways to treat people with B-cell cancers. In this trial, researchers will look at chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These are blood cancers that affect B-cells in the blood, bone marrow, or lymph nodes. The goals of this trial are to learn about: * The safety of MK-1045 and if participants tolerate it. Tolerate means participants will receive trial treatment unless they need to stop treatment due to health problems. * The number of participants who respond. Respond means the number of cancer cells goes down or signs of ca

Trial Details

NCT ID
NCT07709000
Phase
PHASE2
Sponsor
Merck Sharp & Dohme LLC
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • MK-1045
  • Acetaminophen (or similar antipyretic)
  • Diphenhydramine (or similar antihistamine)
  • Dexamethasone
  • Tocilizumab
  • Tocilizumab biosimilar
Locations (sample)
  • Medellín, Antioquia, Colombia|6.245,-75.57151
  • Bogotá, Bogota D.C., Colombia|4.60971,-74.08175
  • Haifa, Israel|32.81303,34.99928
  • Jerusalem, Israel|31.76904,35.21633
  • Jerusalem, Israel|31.76904,35.21633

Key Eligibility Criteria

  • Has histologically confirmed chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) active disease that is relapsed/refractory (r/r) t…
  • Has confirmed CD19-positive disease.
  • If human immunodeficiency virus (HIV)-positive, has well-controlled HIV on antiretroviral therapy.
  • If hepatitis B surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) viral load.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →